EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial

Yunsheng He iD, Christos M Polymeropoulos, Michael A Mohrman, Sunny O Truslow, Changfu Xiao, Yukun Wu, Gunther Birznieks, Mihael H Polymeropoulos

The British Journal of Psychiatry · 2025-07 · 227 (1) · 473-480

DOI: 10.1192/bjp.2025.84 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The British Journal of Psychiatry, online erschienen am 09.05.2025. Verfasst von Yunsheng He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vanda Pharmaceuticals, Washington, DC, USA. Hauptthemen laut MEDLINE: alpha7 Nicotinic Acetylcholine Receptor, Anti-Anxiety Agents, Anxiety, Anxiety Disorders. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the high prevalence of social and performance anxiety, current treatments do not meet the full needs of patients. Development of novel anxiolytics with rapid onset of action for on-demand treatment of social and performance anxiety is an active area of clinical research.

Aims

To examine the anxiolytic effect of VQW-765, an α7-nAChR agonist, in subjects with performance anxiety.

Method

We conducted a randomised, double-blind, placebo-controlled trial of 230 adults with a history of public speaking anxiety. Participants were randomly assigned to receive a single oral dose of 10 mg VQW-765 ( n = 116) or placebo ( n = 114), followed by a Trier Social Stress Test (TSST). Anxiety levels were assessed by the Subjective Units of Distress Scale (SUDS). Heart rate was monitored during the TSST. Plasma concentration of VQW-765 was measured after the TSST.

Results

Subjects receiving VQW-765 showed a trend of improvement in intensity of anxiety, as measured by the SUDS, during the performance phase of a TSST compared with placebo ( P = 0.1443). Females showed a larger magnitude and significant response to VQW-765 ( P = 0.034). The pharmacokinetic/pharmacodynamic analysis observed an inverted U-shaped exposure–response relationship. Subjects in the middle 50% quantiles of VQW-765 plasma concentration showed significant improvement in the SUDS rating compared with placebo ( P = 0.033); however, subgroup analysis revealed this was true only for females ( P = 0.005). VQW-765 was safe and well tolerated.

Conclusions

This is the first study showing anxiolytic effect of an α7-nAChR agonist in humans. VQW-765 is a promising candidate to be developed for on-demand treatment of social anxiety disorder.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

alpha7 Nicotinic Acetylcholine ReceptorAnti-Anxiety AgentsAnxietyAnxiety DisordersNicotinic AgonistsAdultFemaleHumansMaleMiddle AgedYoung AdultDouble-Blind MethodTreatment Outcome

Stichwörter der Autor:innen

Performance anxietyTrier Social Stress Testalpha-7 nicotinic acetylcholine receptorsocial anxiety disorder

Substanzen

alpha7 Nicotinic Acetylcholine ReceptorAnti-Anxiety AgentsNicotinic Agonists

Autor:innen und Institutionen

  • Vanda Pharmaceuticals, Washington, DC, USA.

ORCID-Profile: Yunsheng He

Zitieren

APA

He, Y., Polymeropoulos, C. M., Mohrman, M. A., Truslow, S. O., Xiao, C., Wu, Y., Birznieks, G., & Polymeropoulos, M. H. (2025). Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. The British Journal of Psychiatry, 227(1), 473-480. https://doi.org/10.1192/bjp.2025.84

Vancouver

He Y, Polymeropoulos CM, Mohrman MA, Truslow SO, Xiao C, Wu Y, et al. Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. The British Journal of Psychiatry. 2025;227(1):473-480. doi:10.1192/bjp.2025.84

BibTeX
@article{He2025,
  author = {He, Yunsheng and Polymeropoulos, Christos M and Mohrman, Michael A and Truslow, Sunny O and Xiao, Changfu and Wu, Yukun and Birznieks, Gunther and Polymeropoulos, Mihael H},
  title = {Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial},
  journal = {The British Journal of Psychiatry},
  year = {2025},
  volume = {227},
  number = {1},
  pages = {473--480},
  doi = {10.1192/bjp.2025.84}
}
Kostenlos starten →